Trabectedin Continuation vs. Interruption in Soft-Tissue Sarcoma

Share this content:

the Cancer Therapy Advisor take:

According to a new study published in the journal The Lancet Oncology, researchers have found that it is better to continue trabectedin treatment until disease progression rather than discontinue therapy after six treatment cycles in patients with advanced, doxorubicin-refractory soft-tissue sarcoma.

For the open-label, non-comparative, multicenter, phase II study, researchers administered trabectedin 1.5mg/m2 as a continuous 24-hour IV infusion every 3 weeks to patients with advanced soft-tissue sarcomas who had previously received doxorubicin-based chemotherapy.

After six treatment cycles, patients free from disease progression were randomly assigned to continue treatment or discontinue treatment. Of 178 enrolled, 91 had not progressed after six cycles, and 53 were randomly assigned to either of the groups.

Results showed that the 6-month progression-free survival was 51.9% (95% CI: 31.9 - 68.6) and 23.1% (9.4 - 40.3) in the continuation group and interruption group, respectively (P = 0.0200). The frequency of adverse events was similar in both groups.

The authors conclude that trabectedin discontinuation should not be recommended in those who have not progressed after six treatment cycles.

AMG-337 caused responses in patients with MET-amplified gastroesophageal junction, gastric cancer, a
Researchers have found that it is better to continue trabectedin treatment until disease progression rather than discontinue therapy.
The authors report the final analysis of a phase 2 trial investigating the clinical benefit of continuation of trabectedin treatment until progression versus interruption of therapy after six treatment cycles in patients with advanced soft-tissue sarcoma.
READ FULL ARTICLE From Mdlinx

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters